Nextcure announces new appointments to its board of directors

Beltsville, md., oct. 04, 2021 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the appointments of ellen g. feigal, m.d., and anne borgman, m.d., to its board of directors.

NXTC Ratings Summary

NXTC Quant Ranking